Johnson & Johnson (JNJ)
149.59
+0.47
(+0.32%)
USD |
NYSE |
Apr 23, 16:00
149.56
-0.03
(-0.02%)
After-Hours: 20:00
Johnson & Johnson Revenue (Annual): 85.16B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 85.16B |
| December 31, 2022 | 79.99B |
| December 31, 2021 | 78.74B |
| December 31, 2020 | 82.58B |
| December 31, 2019 | 82.06B |
| December 31, 2018 | 81.58B |
| December 31, 2017 | 76.45B |
| December 31, 2016 | 71.89B |
| December 31, 2015 | 70.07B |
| December 31, 2014 | 74.33B |
| December 31, 2013 | 71.31B |
| December 31, 2012 | 67.22B |
| December 31, 2011 | 65.03B |
| December 31, 2010 | 61.59B |
| December 31, 2009 | 61.90B |
| December 31, 2008 | 63.75B |
| December 31, 2007 | 61.10B |
| December 31, 2006 | 53.32B |
| December 31, 2005 | 50.51B |
| December 31, 2004 | 47.35B |
| Date | Value |
|---|---|
| December 31, 2003 | 41.86B |
| December 31, 2002 | 36.30B |
| December 31, 2001 | 32.32B |
| December 31, 2000 | 29.17B |
| December 31, 1999 | 28.01B |
| December 31, 1998 | 24.00B |
| December 31, 1997 | 22.63B |
| December 31, 1996 | 21.62B |
| December 31, 1995 | 18.84B |
| December 31, 1994 | 15.73B |
| December 31, 1993 | 14.14B |
| December 31, 1992 | 13.75B |
| December 31, 1991 | 12.45B |
| December 31, 1990 | 11.23B |
| December 31, 1989 | 9.757B |
| December 31, 1988 | 9.00B |
| December 31, 1987 | 8.012B |
| December 31, 1986 | 7.003B |
| December 31, 1985 | 6.421B |
| December 31, 1984 | 6.124B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
78.74B
Minimum
2021
85.16B
Maximum
2023
81.71B
Average
82.06B
Median
2019
Revenue (Annual) Benchmarks
| Amgen Inc | 28.19B |
| Gilead Sciences Inc | 27.12B |
| Eli Lilly and Co | 34.12B |
| Merck & Co Inc | 60.12B |
| Shockwave Medical Inc | 730.23M |